Avastin offers hope to CME sufferers

Article

Intravitreal bevacizumab (Avastin; Genentech) appears to be a safe and effective treatment in the management of refractory inflammatory cystoid macular oedema.

Intravitreal bevacizumab (Avastin; Genentech) appears to be a safe and effective treatment in the management of refractory inflammatory cystoid macular oedema (CME), according to a report published in the January issue of Retina.

Friederike Mackensen from the University of Heidelberg and colleagues from the University of Duisburg-Essen, Duisburg, Germany reviewed 11 eyes of 10 patients with persistent CME who subsequently had been treated with intravitreous bevacizumab 1.25 or 2.5 mg. Improvement was gauged by visual acuity (VA) gain ≥2 lines and central retinal thickness reduction, as observed by optical coherence tomography (OCT).

Reductions in central retinal thickness were observed as early as two weeks, with a mean foveal thickness reduction of 127.2 µm at four-weeks. Concurrent improvement in VA was observed in four of the 10 subjects and was unchanged in others. Four patients received two injections and five patients received three injections. Except for progression of cataract in one eye, no ocular or systemic adverse events were recorded.

The researchers believe that intravitreal bevacizumab could offer a safe and effective treatment for the management of refractory inflammatory CME, despite the effect being transient.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Related Content
© 2025 MJH Life Sciences

All rights reserved.